Literature DB >> 30538325

While waiting for a vaccine: opportunities for optimization of neonatal group B streptococcal (GBS) disease prevention in Israel.

Dan Waisman1, Ayala Gover2, Michal Molad2, Reuven Kedar3, Avi Rotschild2, William E Benitz4.   

Abstract

OBJECTIVE: To quantify effects of different strategies for decreasing neonatal early onset GBS sepsis (EOGBS) in Israel. STUDY
DESIGN: A risk allocation model for EOGBS among infants ≥ 35w was adapted to Israeli data. Effects of strategies for antepartum (APS) and intrapartum (IPS) screening, and intrapartum (IAP) and/or postpartum antibiotic prophylaxis (PAP) were calculated.
RESULTS: Estimated EOGBS attack rates (AR) with APS in 90%, IAP in 90%, may reduce AR to 0.18/1000. A rapid intrapartum test would further decrease AR to 0.16/1000, while reducing IAP from 21.3 to 12.5% of women. For babies with risk factors and GBS+ who do not receive IAP, further risk reduction could be achieved by PAP.
CONCLUSION: IAP remains the main intervention to decrease EOGBS. IAP and PAP together may reduce EOGBS present incidence by 40%. Combining rapid intrapartum screening with selective IAP and selective PAP for remaining gaps, would be the most efficient strategy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30538325     DOI: 10.1038/s41372-018-0289-2

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  3 in total

Review 1.  [Prevention of perinatal group B Streptococcus disease in light of an unknown maternal carriage rate in Israel].

Authors:  R Haimov-Kochman; R Bromiker; A Milwidsky
Journal:  Harefuah       Date:  2000-06-15

2.  Intrapartum prophylaxis of group B streptococcal disease in Israel: guidelines and practice.

Authors:  Orly Goldstick; Peter Jakobi
Journal:  Isr Med Assoc J       Date:  2005-03       Impact factor: 0.892

3.  Risk factors for carriage of group B streptococcus in southern Israel.

Authors:  Dror Marchaim; Mordechai Hallak; Limor Gortzak-Uzan; Nechama Peled; Klaris Riesenberg; Francisc Schlaeffer
Journal:  Isr Med Assoc J       Date:  2003-09       Impact factor: 0.892

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.